logo
  

Publicis Groupe Q3 Organic Sales Up 1.2% - Quick Facts

Publicis Groupe (PGPEF.PK,PUBGY.PK) reported that its third-quarter consolidated revenue was 2.26 billion euros, down 2.2% from 2.31 billion euros for the corresponding period in 2016. Growth at constant exchange rates was 1.9%. Organic growth stood at 1.2% in the third quarter.

The Group said it benefited from the ramp-up of contributions from accounts gained since the second quarter 2016, in particular those of Walmart, USAA, Asda, Motorola and Lowe's. Organic growth remained impacted by the SapientRazorfish restructuring and the impact on revenue of the ending of non-profitable contracts.

At September 30, 2017, Publicis Groupe's year-to-date revenue stood at 7.11 billion euros compared to 7.07 billion euros in 2016, an increase of 0.6%. Organic growth stood at 0.3% at September 30, 2017.

Looking forward, the Group said it expects better organic growth in the second half of 2017 by comparison with the first half of the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lincoln Park, New Jersey -based ConSup North America Inc. is recalling around 85,984 pounds of ready-to-eat or RTE sliced prosciutto ham product produced in Germany without the benefit of equivalent inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and...

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT